Pattern of relapse and dosimetric analysis of a single dose 19 Gy HDR-brachytherapy phase II trial
Author:
Funder
Basque Country Government
Publisher
Elsevier BV
Subject
Radiology, Nuclear Medicine and imaging,Oncology,Hematology
Reference17 articles.
1. High dose rate brachytherapy for prostate cancer: a prospective toxicity evaluation of a one day schedule including two 13.5 Gy fractions;Nagore;Radiother Oncol J Eur Soc Ther Radiol Oncol,2018
2. High-dose-rate brachytherapy as monotherapy for intermediate- and high-risk prostate cancer: clinical results for a median 8-year follow-up;Yoshioka;Int J Radiat Oncol,2016
3. Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: early toxicity and quality-of life results from a randomized phase II clinical trial of one fraction of 19Gy or two fractions of 13.5 Gy;Morton;Radiother Oncol J Eur Soc Ther Radiol Oncol,2017
4. Health-related-quality-of-life and toxicity after single fraction 19 Gy high-dose-rate prostate brachytherapy: phase II trial;Gomez-Iturriaga;Radiother Oncol J Eur Soc Ther Radiol Oncol,2018
5. Five-year outcomes of a single-institution prospective trial of 19-Gy single-fraction high-dose-rate brachytherapy for low- and intermediate-risk prostate cancer;Siddiqui;Int J Radiat Oncol Biol Phys,2019
Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Single–dose high-dose-rate brachytherapy versus two and three fractions for locally advanced prostate cancer;Radiotherapy and Oncology;2024-10
2. Radiobiological evaluation of the stepping-source effect in single-fraction monotherapy high-dose-rate prostate brachytherapy;Brachytherapy;2023-09
3. Safety and efficacy associated with single-fraction high-dose-rate brachytherapy in localized prostate cancer: a systematic review and meta-analysis;Strahlentherapie und Onkologie;2023-04-24
4. The potential of low-dose-rate brachytherapy with iodine-125 in the treatment of local recurrences of prostate cancer after primary high-dose-rate monotherapy;Journal of Contemporary Brachytherapy;2023
5. Single fraction of HDR brachytherapy for prostate cancer: Results of the SiFEPI phase II prospective trial;Clinical and Translational Radiation Oncology;2022-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3